Author: Morey Adrienne Murali Rajmohan McCarthy Stanley Mann Graham Scolyer Richard
Publisher: Ashgate Publishing Ltd
ISSN: 0031-3025
Source: Pathology, Vol.41, Iss.4, 2009-06, pp. : 383-387
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Background: Accurate classification of primary melanocytic tumours as benign or malignant is crucial for prognostic prediction and appropriate patient management. Several chromosomal aberrations have been frequently identified in melanomas, but are absent in melanocytic naevi. We performed four-colour fluorescence in situ hybridisation (FISH) analysis of melanocytic tumours to determine the accuracy of the technique in classifying melanocytic tumours as benign or malignant. Methods: FISH was performed on paraffin-embedded tissue from 40 histologically unequivocal melanocytic tumours (10 metastatic melanomas, 10 primary melanomas and 20 benign melanocytic naevi) using the product Vysis LSI RREB1/LSI MYB/LSI CCND1/CEP 6 probes (Abbott Molecular Laboratories, USA), which is designed to detect the copy number of the RREB1 (6p25), MYB (6q23), and CCND1 (11q13) genes and FISH positivity is defined by means of a scoring algorithm. Results: FISH distinguished the melanomas and the naevi with a sensitivity of 90% (10/10 primary melanoma cases and 8/10 metastatic melanoma cases, respectively), and a specificity of 95%. The most common abnormalities in the melanomas were increased copies of 11q (70%) and 6p (70%), followed by 6q loss relative to cep6 (50%). Fifteen of the 18 positive melanomas were positive by more than one criterion. Conclusions: The results of this study show that FISH, using a panel of four probes, is a sensitive and specific method of classifying benign and malignant melanocytic tumours. The four-colour FISH technique has the potential to assist in the stratification of the subgroup of melanocytic tumours which are difficult to classify using conventional histology.
Related content
Medicare funding for fluorescence in situ hybridisation
Pathology, Vol. 39, Iss. 5, 2007-10 ,pp. :
By Bilous Michael Morey Adrienne Armes Jane Cummings Margaret Francis Glenn
Pathology, Vol. 38, Iss. 2, 2006-04 ,pp. :
By Sumithran Eric Cheah Phaik-Leng Susil Beatrice Looi Lai-Meng
Pathology, Vol. 28, Iss. 4, 1996-11 ,pp. :